 |
|
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn
Clin Mol Hepatol. 2020;26(3):352-363. Published online 2020 May 28 DOI: https://doi.org/10.3350/cmh.2019.0044n
|
|
Citations to this article as recorded by
 High Prevalence of Hepatitis B Virus Drug Resistance Mutations to Lamivudine among People with HIV/HBV Coinfection in Rural and Peri-Urban Communities in Botswana
Bonolo B. Phinius, Motswedi Anderson, Irene Gobe, Margaret Mokomane, Wonderful T. Choga, Basetsana Phakedi, Tsholofelo Ratsoma, Gorata Mpebe, Joseph Makhema, Roger Shapiro, Shahin Lockman, Rosemary Musonda, Sikhulile Moyo, Simani Gaseitsiwe
Viruses.2024; 16(4): 592. CrossRef Bictegravir/Emtricitabine/Tenofovir Alafenomide for the Treatment of HIV/Hepatitis B Virus Co-infection in Patients with Cancer and Transplant Recipients
Jana K Dickter, Justine A Ross
Infectious Diseases.2023; 2(1): 31. CrossRef Old age as a risk factor for liver diseases: Modern therapeutic approaches
Milena Georgieva, Charilaos Xenodochidis, Natalia Krasteva
Experimental Gerontology.2023; 184: 112334. CrossRef Study on the intestinal permeability of lamivudine using Caco-2 cells monolayer and Single-pass intestinal perfusion
Weiyin Huang, Shuang Chen, Lin Sun, Hubin Wwang, Hongqun Qiao
Saudi Journal of Biological Sciences.2022; 29(4): 2247. CrossRef External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2022; 14(3): 711. CrossRef
|